Pluri (PLUR) Stock Price

Pluri Price

NASDAQ·CLOSED
0.93
​
Market closed

Revenue has compounded at 2.5% per year over the past 14 years to 1.02 M USD. Pluri's net margin stands at -2,344.6%, up from -17,624.8% several years earlier.

Pluri stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pluri business model & stock analysis

Pluri Inc, listed under the ticker PLUR with ISIN US72942G2030, is a biotechnology company headquartered in Haifa, Israel. The company operates within the Health Care sector, specifically in the Biotechnology industry. Founded in 2007, Pluri Inc. went public on December 10, 2007. The company employs 123 people and maintains a website at https://pluri-biotech.com/. Pluri Inc. focuses on the development of cell therapies, with its lead indications targeting critical limb ischemia (CLI), recovery following surgery for femoral neck fracture, and acute radiation syndrome. The company's operations encompass research, development, clinical trials, and manufacturing of cell therapeutics and related technologies. Pluri's PLX-PAD and PLX R18 are among its product offerings. The PLX cells utilized by the company are adherent stromal cells (ASCs) expanded through a three-dimensional (3D) process that employs a synthetic scaffold to create an artificial 3D environment for placental-derived stromal cells to grow. These PLX products are administered via standard needle and syringe. The company's cell therapies are in clinical-stage development for various conditions, including cardiovascular, orthopedic, pulmonary, and women's health diseases. Pluri Inc. is engaged in advancing therapeutic solutions through innovative cell-based approaches, aiming to address significant unmet medical needs across multiple therapeutic areas.

Frequently asked questions about Pluri

7 analysts currently rate the Pluri stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Pluri share trades at 0.83 EUR (0.93 USD).

The Pluri share (PLUR) is listed on 4 stock exchanges, including: NASDAQ (PLUR), Frankfurt (Y55.F), München (Y55.MU).

The revenue of Pluri is 1.02 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Pluri is -23.82 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pluri is currently -0.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pluri stock.

The price-to-sales ratio (P/S) of Pluri is currently 9.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pluri stock.

The Eulerpool Quality Score for Pluri is 3/10.

The ISIN of Pluri is US72942G2030. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pluri is A3DQ8D. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pluri is PLUR. The ticker symbol is used to trade Pluri shares on the stock exchange.

Fair ValueTerminal
0.79 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
8,260.16 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Dec 10, 2007
ISIN
US72942G2030
Cusip
72942G104
Market capitalization
9.35 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-0.53
P/S
P/Se
0.99
EV/EBIT
—
P/B Ratio
97.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-200.55 %
Last updated Oct 18, 2026, 2:37 PM

Pluri Peer Group

Pluri Ticker

FRANKFURT · Y55.FMUNICH · Y55.MUNASDAQ · PLURTLV · PLUR.TA

All fundamentals and in-depth analysis of Pluri

Our stock analysis for Pluri stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pluri. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.